Equities analysts forecast that ADMA Biologics, Inc. (NASDAQ:ADMA) will post earnings of ($0.15) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.18) to ($0.12). ADMA Biologics posted earnings of ($0.23) per share in the same quarter last year, which indicates a positive year over year growth rate of 34.8%. The business is expected to report its next earnings report on Wednesday, August 4th.
According to Zacks, analysts expect that ADMA Biologics will report full year earnings of ($0.57) per share for the current financial year, with EPS estimates ranging from ($0.66) to ($0.46). For the next year, analysts expect that the business will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.36) to ($0.22). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Tuesday, May 11th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. ADMA Biologics had a negative net margin of 155.78% and a negative return on equity of 85.82%. The company had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.63 million.
Shares of ADMA opened at $1.85 on Tuesday. ADMA Biologics has a 12 month low of $1.45 and a 12 month high of $4.20. The stock’s 50 day simple moving average is $1.77. The company has a market capitalization of $237.15 million, a PE ratio of -2.37 and a beta of 1.33. The company has a debt-to-equity ratio of 0.89, a current ratio of 8.36 and a quick ratio of 3.92.
Several hedge funds and other institutional investors have recently bought and sold shares of ADMA. AE Wealth Management LLC grew its stake in shares of ADMA Biologics by 8.3% during the fourth quarter. AE Wealth Management LLC now owns 110,500 shares of the biotechnology company’s stock worth $215,000 after buying an additional 8,500 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of ADMA Biologics by 40.1% during the fourth quarter. GSA Capital Partners LLP now owns 327,052 shares of the biotechnology company’s stock worth $638,000 after buying an additional 93,627 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth $45,000. Bank of New York Mellon Corp grew its stake in shares of ADMA Biologics by 7.7% during the fourth quarter. Bank of New York Mellon Corp now owns 208,775 shares of the biotechnology company’s stock worth $406,000 after buying an additional 14,953 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of ADMA Biologics by 6.2% during the fourth quarter. Wells Fargo & Company MN now owns 179,413 shares of the biotechnology company’s stock worth $351,000 after buying an additional 10,506 shares during the last quarter. 39.88% of the stock is currently owned by hedge funds and other institutional investors.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Article: Why are analyst ratings important in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.